(Q37328718)

19 August 2017

1 reference

title

Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review (English)

1 reference

19 August 2017

1 reference

1 reference

4

Pisake Lumbiganon

1 reference

19 August 2017

3

Malinee Laopaiboon

1 reference

19 August 2017

1

Siriwan Tangjitgamol

1 reference

19 August 2017

Sumonmal Manusirivithaya

series ordinal

2

object named as

Sumonmal Manusirivithaya

1 reference

19 August 2017

language of work or name

English

0 references

publication date

18 November 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

112

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

257-264

1 reference

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Intervention debulking surgery in advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Secondary surgical cytoreduction for advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Diagnostic open laparoscopy in the management of advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

The role of surgical reexploration following chemotherapy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Five-year results of cyclic semi-high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem-cell transplantation in patients with advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

The role of interval debulking surgery in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Interval cytoreduction in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

Interval debulking surgery for advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.09.041

10.1016/J.YGYNO.2008.09.041

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference